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ABSTRACT
MYC is a key driver of cellular transformation and is deregulated in most human cancers. Studies of MYC
and its interactors have provided mechanistic insight into its role as a regulator of gene transcription. MYC
has been previously linked to chromatin regulation through its interaction with INI1 (SMARCB1/hSNF5/
BAF47), a core member of the SWI/SNF chromatin remodeling complex. INI1 is a potent tumor suppressor
that is inactivated in several types of cancers, most prominently as the hallmark alteration in pediatric
malignant rhabdoid tumors. However, the molecular and functional interaction of MYC and INI1 remains
unclear. Here, we characterize the MYC-INI1 interaction in mammalian cells, mapping their minimal
binding domains to functionally significant regions of MYC (leucine zipper) and INI1 (repeat motifs), and
demonstrating that the interaction does not interfere with MYC-MAX interaction. Protein-protein
interaction network analysis expands the MYC-INI1 interaction to the SWI/SNF complex and a larger
network of chromatin regulatory complexes. Genome-wide analysis reveals that the DNA-binding regions
and target genes of INI1 significantly overlap with those of MYC. In an INI1-deficient rhabdoid tumor
system, we observe that with re-expression of INI1, MYC and INI1 bind to common target genes and have
opposing effects on gene expression. Functionally, INI1 re-expression suppresses cell proliferation and
MYC-potentiated transformation. Our findings thus establish the antagonistic roles of the INI1 and MYC
transcriptional regulators in mediating cellular and oncogenic functions.
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Introduction
The dynamic organization of chromatin in conjunction with
transcription factors and chromatin regulatory proteins is criti-
cal to the coordination of gene expression. In recent years,
deregulated epigenetic proteins and processes have been shown
to mediate oncogenesis.1,2 The c-MYC (MYC) protein is key
driver of cellular transformation and is deregulated in more
than half of all human cancers.3 As a transcription factor of the
basic helix-loop-helix leucine zipper (bHLHLZ) family, MYC
binds to site-specific E-box sequences to regulate gene tran-
scription together with its heterodimeric partner, MAX.4,5 This
interaction is critical for the diverse set of biological functions
that MYC controls, including cell growth, proliferation, apo-
ptosis, and transformation.6,7 MYC interaction with additional
chromatin regulators can modulate the transcriptional activity
and specificity of MYC, though this area is underexplored.8,9
An early link between MYC and epigenetic regulation is the
interaction of MYC and INI (SMARCB1/hSNF5/BAF47), a
core member of the SWI/SNF chromatin remodeling com-
plex.10 INI1 is a potent tumor suppressor as evident by mouse
models and the identification of biallelic inactivating mutations
in nearly all cases of pediatric malignant rhabdoid tumors.11-13
Moreover, mutations in INI1 and other subunits of the SWI/
SNF complex have been identified in recent whole genome and
exome sequencing studies in a wide spectrum of cancer types,
making this complex one of the most frequently mutated chro-
matin regulatory complexes in human cancers.14,15 Despite this
striking association with cancer, the mechanistic understanding
of how INI1 contributes to oncogenesis and its biological and
molecular link to MYC remain unclear. Herein, we characterize
the molecular interaction and transcriptional network of MYC
and INI1 and demonstrate their opposing roles in regulating
transcription and cellular transformation.
Results
MYC interacts with INI1 and is dependent on the leucine
zipper region
Evidence of a MYC-INI1 interaction was previously demon-
strated in vitro and in HEK293T cells.10 To determine whether
this interaction occurs in other cell types, we performed endog-
enous co-immunoprecipitation on a panel of cell lines derived
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from breast (SK-BR3, T47D) and lung (A549, NCI-H520) car-
cinomas. Nuclear extracts were immunoprecipitated with a
MYC-specific antibody (N262) or immunoglobulin G (IgG)
control, followed by immunoblotting to detect endogenous
INI1 and MYC (Fig. 1A). INI1 co-immunoprecipitated with
MYC in all 4 cell lines, indicating an endogenous interaction in
multiple cell types.
To validate that this interaction is direct and begin to nar-
row in on the regions important for this interaction, we next
performed an in vitro binding assay using a glutathione-S-
transferase (GST)-tagged INI1 fragment encompassing the
amino acid residues 183 to 294 (GST-INI1 183–294) with puri-
fied recombinant His-tagged MYC 250–439 and 353–434
(Fig. 1B). GST-INI1 183–294 or GST control was bound to glu-
tathione agarose beads and subsequently incubated with the
His-MYC C-terminal fragments. Binding of both MYC frag-
ments was observed with GST-INI 183–294 but not GST con-
trol (Fig. 1C). Thus, INI1 residues 183–294 directly bind MYC
residues 353–434, which contain the bHLHLZ region, in the
absence of additional cofactors.
To further identify the minimal functional region of MYC
required for interaction with INI1 in mammalian cells, we eval-
uated a panel of previously characterized C-terminal scanning
mutants16 for their ability to interact with endogenous INI1.
The MYC deletion mutants spanned residues 265–433, which
included MYC homology box (MB) IIIb and IV, as well as the
Figure 1. MYC interacts with INI1 and is dependent on the leucine zipper region. (A) Nuclear extracts from SK-BR3, T47D, A549, and NCI-H520 cells were immunoprecipi-
tated with a MYC-specific antibody (N262) or species-matched immunoglobulin G (IgG) and immunoblotted for INI1 and MYC expression, with 10% input included to
assess protein expression. (B) Schematic representations of INI1 (GST-INI 183–294) and MYC (His-MYC 250–439 and 353–434) recombinant fusion proteins, with protein
regions and amino acid positions indicated. Rpt I: Repeat I, Rpt II: Repeat II, b: basic region, HLH: helix-hoop-helix, LZ: leucine zipper. (C) Recombinant proteins were bacte-
rially expressed and purified. GST or GST-INI1 183–294 (100 mg) were bound to glutathione sepharose beads and incubated with 100 mg of His-MYC 250–439 or His-MYC
353–434. Complexes were eluted and resolved by SDS-PAGE and visualized by Coomassie staining. (D) Schematic representations of wild-type MYC and C-terminal scan-
ning deletion mutants. MB: MYC homology box. (E) Nuclear extracts of HO15.19 MYC deletion mutant panel were immunoprecipitated with a MYC-specific antibody or
IgG and immunoblotted for INI1 and MYC expression, with 10% input included. Three independent experiments were performed with representative results shown for all
immunoblots.
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basic, HLH, and LZ regions (Fig. 1D). The mutants were stably
introduced into the MYC-null HO15.19 cells to eliminate the
confounding effects of endogenous MYC. Nuclear extracts
were immunoprecipitated with a MYC-specific antibody (3C7)
that detects all C-terminal mutants,17 and immunoblotted for
the presence of INI1. In this system, both alternatively spliced
isoforms18 of INI1 were expressed and co-immunoprecipitated
with wild-type MYC, while the MYC-null control showed no
INI1 co-immunoprecipitation (Fig. 1E). Deletion of residues
265–317 and the basic region did not abrogate interaction with
either INI1 isoform, while deletion of HLH retains interaction
with the lower molecular weight isoform (Fig. 1E). Neither
INI1 isoforms co-immunoprecipitated with MYC lacking the
LZ (Fig. 1E). The MYC LZ region (residues 407–439) thus
encompasses the minimal site of interaction with both INI1
isoforms.
The MYC-INI1 interaction does not interfere with the MYC-
MAX interaction
As the MYC-INI1 interaction is dependent on the LZ region,
and MAX interacts with MYC through the HLHLZ region, we
next sought to investigate how INI1 affects the MYC-MAX
interaction. To determine if MYC can bind both MAX and
INI1, we immunoprecipitated whole cell extracts from 2 human
cell lines (NCI-H520 and SK-BR3) with a MYC-specific anti-
body or IgG, and subsequently assayed for INI1 and MAX
detection by immunoblot. Both INI1 and MAX were co-immu-
noprecipitated with MYC (Fig. 2A), suggesting MYC interacts
with both partner proteins in endogenous settings.
To determine whether INI1 interacts with the MYC-MAX
heterodimer, we used the HO15.19 MYC-EG/MAX-EG sys-
tem.6 These MYC-null cells have been stably infected with
mutant forms of human MYC (MYC-EG) and MAX (MAX-
EG), whose key residues within their LZ regions have been
exchanged, thereby disabling heterodimerization with their
respective endogenous partner proteins, but maintaining the
interaction with each other (Fig. 2B). Concomitant expression
of MYC-EG and MAX-EG is necessary to mimic wild-type
MYC function in restoring proliferation, transformation, auto-
suppression, and apoptosis.6,7,19 We performed reciprocal
MYC and INI1 co-immunoprecipitation and demonstrated
that MYC and INI1 interact in cells expressing both MYC-EG
and MAX-EG, and their interaction remained intact in cells
expressing only MYC-EG, indicating that the MYC-INI1 inter-
action is not dependent on MYC-MAX heterodimerization
Figure 2. MYC and INI1 interact independently of MYC-MAX heterodimerization. (A) Whole cell extracts from SK-BR3 and NCI-H520 cells were immunoprecipitated with a
MYC-specific antibody or IgG and immunoblotted for INI1, MAX, and MYC expression, with 10% input included. (B) Schematic representation of LZ regions of MYC, MAX,
MYC-EG, and MAX-EG. Lines and bold colored letters indicate positions of exchange residues. (C) Whole cell extracts from HO15.19 cells expressing ectopic wild-type
MYC, MYC-EG, MYC-EG/MAX-EG, MAX, or vector control were immunoprecipitated with MYC, INI1, or MAX antibodies or IgG control and immunoblotted for MYC, INI1,
and MAX detection, with 10% input included. Three independent experiments were performed with representative results shown for all immunoblots.
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(Fig. 2C, left). Reciprocal co-immunoprecipitation of MAX and
INI1 did not show interaction of MAX and INI1 in the absence
of MYC (Fig. 2C, right). Taken together, these results indicate
that INI1 interaction with MYC does not depend on or inter-
fere with MYC-MAX heterodimerization.
MYC interacts with the conserved Repeat I and II regions of
INI1
The INI1 protein comprises an N-terminal region of uncharac-
terized structure and function and a C-terminal SNF5 Homol-
ogy Domain (residues 186 to 378; Fig. 3A). The latter domain
contains two imperfect repeat regions (Repeats (Rpt) I and II)
that are nodes for protein-protein interaction.10,20-23 To investi-
gate the region of INI1 required for the MYC-INI1 interaction
in mammalian cells, we generated a series of FLAG-tagged
truncation mutants and deletion mutants within this region
(Fig. 3A). To assess the mutants’ subcellular localization and
expression, HEK293Tv cells were transiently transfected and
then fractionated for chromatin, nuclear, and cytoplasmic frac-
tions. Expression of FLAG-tagged INI1 and INI1 mutants and
fraction-specific proteins (tubulin for cytoplasmic fraction and
acetylated histone H3 for chromatin fraction) was assessed by
immunoblotting (Fig. 3B). All mutants were expressed in the
nuclear and/or chromatin fractions. The Rpt I mutant was
localized predominantly in the nuclear fraction, although lon-
ger autoradiographic exposures of immunoblots demonstrated
evidence of weak expression in the chromatin fraction (data
not shown). Thus, the expression and chromatin localization of
the panel of INI1 mutants can be applied to map regions of
interaction with MYC.
To identify the minimal region of interaction with MYC in
cells, we performed co-immunoprecipitation analysis from
whole cell extracts in transiently transfected HEK293Tv cells.
We demonstrated that INI1 fragments of Rpt II (residues 259–
319), residues 183–294, and 245–294, but not Rpt I, co-immu-
noprecipitated with MYC (Fig. 3C, left), suggesting that resi-
dues 259–294 of Rpt II were sufficient for MYC interaction.
However, since the Rpt I fragment was expressed in the nuclear
fraction, but not abundantly expressed in the chromatin frac-
tion, it is difficult to evaluate whether the lack of interaction
with this Rpt I fragment is due to its lack of localization to
chromatin or because this region is not essential for interaction.
In addition, co-immunoprecipitation of MYC and three INI1
Figure 3. MYC interacts with the conserved Repeat motifs of INI1. (A) Schematic representation of wild-type INI1 and truncation and deletion mutants, with protein
regions and amino acid positions indicated. NLS: nuclear localization signal. (B) HEK293Tv cells were transiently transfected with wild-type INI1 or INI1 mutants. Cells
were harvested for fractionation 48 hours post-transfection. Cytoplasmic (C), nuclear (N), and chromatin (Chr) fractions were immunoblotted for INI1 expression, with
tubulin and acetylated histone 3 (AcH3) as cytoplasmic and chromatin fraction controls, respectively. (C) Whole cell extracts from transiently transfected HEK293Tv cells
were immunoprecipitated with a MYC-specific antibody or IgG and immunoblotted for INI1 (with FLAG antibody) and MYC expression, with 5% input included. Three
independent experiments were performed with representative results shown for all immunoblots.
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deletion mutants lacking Rpt I (DRpt I), residues 183–294
(D183–294), or 245–294 (D245–294) demonstrated MYC inter-
action with all three deletion mutants (Fig. 3C, right). These
results suggest that multiple regions of INI1, including the two
imperfect repeat motifs (Rpt II residues 259–294 and Rpt I) are
likely to interact with MYC.
MYC and INI1 interact with chromatin complexes
To extend the interaction network of MYC and INI1, we ana-
lyzed previously reported protein-protein interactions of MYC,
MAX, and INI1. We determined an extensive network of pro-
teins with connection to the MYC-MAX-INI1 complex, sug-
gesting the MYC-INI1 interaction may be part of a larger
transcriptional complex network (Fig. S1). In addition to mem-
bers of the SWI/SNF complex, many of the proteins in this net-
work belong to other multi-subunit complexes, such as the
NuA4 and STAGA histone acetyltransferase complexes, Sin3
and NuRD histone deacetylase complexes, and MLL histone
methyltransferase complexes (Fig. S1). Proteins of the SWI/
SNF complex and these other chromatin regulatory complexes
were also identified as MYC-interacting proteins in our recent
proteomic study of the MYC interactome.24 This suggests that
the MYC-INI1 complex may involve other chromatin regula-
tory complexes and proteins to modulate transcriptional activ-
ity and the epigenetic landscape.
MYC and INI1 share common target genes and oppositely
regulate gene expression
Having established the physical interaction of MYC and INI1,
we next investigated the DNA regions and target genes that
MYC and INI1 share. We utilized chromatin immunoprecipita-
tion sequencing (ChIP-seq) datasets for MYC and INI1 in
HeLa-S3 cells from the Encyclopedia of DNA Elements
(ENCODE) Consortium.25,26 We determined that MYC and
INI1 have significant coincident DNA-binding peaks using a
peak intersection analysis (BEDTools)27 and Genome Structure
Correction (GSC)28 statistical significance test (pD7.01£10¡9).
Of the 10,226 MYC peaks and 7,780 INI1 peaks, 2,690 were
overlapping, corresponding to 26% of total MYC peaks and
35% of total INI1 peaks (Fig. 4A). We next determined the
genomic regions on which MYC and INI1 co-occupy. Pro-
moters were defined as regions 3 kb up- and downstream of
transcriptional start sites (TSSs) and putative enhancers were
defined as regions 50 kb up- and downstream of TSSs that also
overlap with the enhancer histone mark, H3K4me1. Based on
these criteria, out of the 2,690 MYC-INI1 peaks, 1,602 peaks
(60%) mapped to promoters, 575 peaks (21%) mapped to puta-
tive enhancers, and the remaining peaks were located at other
regions (Fig. 4B). Thus, the MYC-INI1 interaction may regulate
target gene transcription from multiple regulatory loci. To
identify target genes that may be regulated by MYC and INI1,
we used Binding and Expression Target Analysis (BETA)29 to
locate the nearest gene to a peak that is bound by both MYC
and INI1 and identified 3,279 genes that may be regulated by
MYC and INI1 (Fig. 4C and Table S1). Gene ontology (GO)
analysis for biological processes showed enrichment of genes
related to translation, RNA and DNA processing and
metabolism, cell death, and cell cycle (Fig. 4C and Table S2).
Taken together, our results indicate that INI1 can bind to a
large subset of MYC target genes.
To further understand MYC and INI1 chromatin binding
and their effects on gene expression, we utilized the INI1-
null human rhabdoid tumor cell line G401, which lacks
detectable INI1 protein and mRNA expression due to a
homozygous deletion mutation.30 INI1 is deleted in nearly
all cases of pediatric malignant rhabdoid tumors.13 This
aggressive disease lacks targeted therapeutic options31 and is
a model tumor type to study the molecular functions of
INI1 in the oncogenic process. Ectopic MYC and FLAG-
tagged INI1 or their respective vector (GFP and pBABEpuro
(pBp)) controls were sequentially and stably introduced into
these cells through retroviral infection, and their expression
was confirmed by immunoblot analysis (Fig. 5A). We per-
formed ChIP-qPCR to determine INI1 and MYC binding
on a series of MYC target genes involved in processes such
as cell cycle, cellular metabolism, and ribosomal and RNA
processing. INI1 was immunoprecipitated with a FLAG
antibody. Its binding was not evident in INI1-null cells, but
was significantly enriched at the promoters of MYC acti-
vated genes (CCND1, CCNE2, CDK4, LDHA, and NCL) and
MYC repressed genes (CDKN1A, CDKN2B, GADD45A,
HES1) in G401 cells introduced with INI1 (Fig. 5B). A
region in chromosome 6 (chr6) was used as a negative con-
trol region. Endogenous MYC binding was confirmed at
these target genes, with increased or similar levels of bind-
ing when ectopic MYC was introduced (Fig. 5C, light
orange and light teal bars). In the presence of INI1, endoge-
nous MYC binding was not significantly affected at most
target genes, but was decreased at GADD45A (Fig. 5C, light
and dark orange bars). In cells with ectopic MYC and INI1,
MYC binding was significantly decreased at several target
genes (CDK4, HSPE1, NCL, CDKN1A, CDKN2B, and
GADD45A) compared with cells expressing only ectopic
MYC (Fig. 5C, light and dark teal bars). These data show
that INI1 binds to MYC target gene promoters and may
affect deregulated MYC binding to a subset of target genes.
We next evaluated the mRNA expression of a series of
MYC activated and repressed genes in this panel of G401
cells (Figs. 5D and S2). Comparing vector control G401
cells to G401 cells with ectopic INI1 expression, MYC acti-
vated genes were consistently down-regulated and MYC
repressed genes were up-regulated. With ectopic MYC
expression, the majority of MYC activated genes were fur-
ther up-regulated, while MYC repressed genes were trend-
ing toward down-regulation or not significantly affected;
this may be because these genes were already expressed at
low levels in G401 cells and cannot be further repressed. In
cells expressing both ectopic MYC and INI1, most MYC
activated genes were down-regulated and MYC repressed
genes were up-regulated compared to cells expressing
ectopic MYC only. Interestingly, INI1 binding showed sig-
nificant enrichment at the MYC promoter with ectopic
MYC expression (Fig. 5B), but the expression of MYC
mRNA was not significantly impacted by INI1 (Fig. S2).
However, MYC protein level was decreased in the presence
of INI1 (Fig. 5A), suggesting INI1 may also regulate MYC
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levels through post-translational means. Collectively, these
results demonstrate that INI1 has opposing effects on the
expression of MYC target genes compared to MYC.
INI1 abrogates MYC-potentiated transformation
As MYC and INI1 bind to and regulate the expression of key cell
cycle genes (Figs. 4C and 5), we sought to determine their effects
on cell proliferation (Fig. 6A). G401 cells expressing ectopic MYC
proliferated similarly as parental and vector control cells with a
doubling time of approximately 17 hours. Ectopic expression of
INI1 slowed proliferation compared to control cells, increasing
doubling time to 24 hours, while ectopic INI1 andMYC increased
doubling time to 20 hours. This suggests that ectopic MYC
expression can partially rescue INI1 inhibited proliferation.
We next evaluated whether INI1 affects MYC-potentiated
transformation by assaying anchorage-independent colony for-
mation in soft agar (Fig. 6B). Parental and vector control G401
cells had similar colony forming ability. Ectopic MYC potentiated
colony formation by approximately five-fold relative to control
cells. Thus, the transforming ability of G401 cells was not satu-
rated by the activity of endogenous MYC because ectopic MYC
expression can further potentiate colony formation. Conversely,
INI1 fully abrogated colony formation in control and ectopic
MYC expressing cells. This suggests that INI1 has the capacity to
counter the transforming ability of G401 cells with endogenous
Figure 4. INI1 binds to a subset of MYC DNA-binding regions and target genes. (A) ChIP-seq datasets from ENCODE for MYC and INI1 in HeLa-S3 cells were analyzed for
overlapping DNA-binding regions by intersecting MYC and INI1 peaks (BEDTools). The numbers of overlapping and non-overlapping peaks are displayed in the Venn dia-
gram. Statistical significance is determined by the Genome Structure Correction (GSC) test. (B) The 2,690 MYC and INI1 common peaks were mapped to genomic regions,
including promoters (TSS § 3 kb) and putative enhancers (TSS § 50 kb overlapping with H3K4me1 regions) using BETA. The percent of peaks mapping to each region is
shown, with the number of peaks indicated above each bar. (C) Target genes of the 2,690 MYC and INI1 common peaks were determined by proximity using BETA. GO
analysis for biological processes (BP) was performed and the top 15 terms are shown with their adjusted p values. The number of genes belonging to each GO BP term is
indicated beside each bar.
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and ectopic levels of MYC. Taken together, these results establish
the opposing functional association between MYC and INI1, in
which MYC potentiates and INI1 suppresses cellular transforma-
tion in rhabdoid tumor cells.
Discussion
MYC and INI1 are well established oncoprotein and tumor
suppressor, respectively, yet their molecular interaction and
biological interplay have been largely unexplored since the ini-
tial description of their physical interaction.10 Here, we charac-
terize the molecular interaction of MYC and INI1 and
demonstrate an antagonistic relationship between the two pro-
teins in regulating transcription and driving oncogenic pro-
cesses. We show that endogenous MYC and INI1 interact in
different cell types and this interaction is direct and indepen-
dent of additional co-factors, including MAX. Interestingly,
MYC and INI1 co-immunoprecipitate in two cell lines deficient
for members of the SWI/SNF complex (A549 is BRG1
Figure 5. MYC and INI1 bind to common target genes and have opposing effects on gene expression in rhabdoid tumor cells. (A) Left: G401 rhabdoid tumor cells were
retrovirally infected with MYC or GFP vector control. Expression of MYC was confirmed by immunoblotting. Right: G401 expressing ectopic MYC or GFP control were sub-
sequently retrovirally infected with FLAG-INI1 or pBABEpuro (pBp) vector control. MYC and INI1 (using INI1 and FLAG antibodies) expression was confirmed by immuno-
blotting. (B) ChIP-qPCR was performed on the panel of G401 cells on the promoters of a series of MYC activated (CCND1, CCNE2, CDK4, HSPE1, LDHA, and NCL), MYC
repressed (CDKN1A, CDKN2B, GADD45A, HES1) genes, and the MYC gene. A region in chromosome 6 (chr6) was used as negative control. FLAG-INI1 was immunoprecipi-
tated with a FLAG-specific antibody. Immunoprecipitated DNA is represented as a percentage of total input DNA (% input). Mean % input § SEM for 3 independent
experiments is shown.  p<0.05,  p<0.01,  p<0.001,  p<0.0001, one-way ANOVA with Tukey post test. (C) ChIP-qPCR was performed as in Figure 6B, but immu-
noprecipitated with a MYC-specific antibody. Mean % input § SEM for 3 independent experiments is shown.  P < 0.05,  P < 0.01,  P < 0.001,  P < 0.0001, one-
way ANOVA with Tukey post test. (D) mRNA expression of a series of MYC activated and repressed genes was evaluated in the G401 panel by qPCR. Gene expression is
presented as log2(fold change) relative to G401 cells with both empty vectors. The heatmap depicts degree of up-regulated (red) and down-regulated (blue) expression
changes, with each small square representing the value of one biological replicate. Specific expression values and statistical significance are shown in Figure S1.
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(SMARCA4)-deficient and T47D is ARID1A-deficient). Can-
cers deficient for BRG1 or ARID1A have been shown to retain
a residual SWI/SNF complex containing INI1 and their highly
similar subunits BRM (SMARCA2) or ARID1B, respec-
tively.32,33 We and others observe that MYC can interact with
other members of the SWI/SNF complex,24,34 but whether these
interactions occur directly or are mediated by INI1 remains
unknown. MYC may therefore interact with INI1 despite the
loss or alteration of other SWI/SNF complex members or
through interaction with multiple members of the complex.
We have also delineated their minimal regions of interaction in
mammalian systems. MYC interacts with both functionally
similar INI1 isoforms18 through the LZ region, which is essen-
tial for MAX dimerization as well as the regulation of MYC-
dependent proliferation and transformation.6,7 Our findings in
mammalian cells support and refine the in vitro study that
defined the MYC bHLHLZ as the region of interaction for INI1
and showed deletion of LZ can attenuate interaction with
INI1.10
All known INI1 interactors, including MYC, map their
binding regions to the SNF5 Homology Domain, which con-
tains Rpt I and II.35 Our interaction mapping have determined
the INI1 minimal binding region contains a portion of Rpt II
(residues 259–294). Previous two-hybrid results also show that
the region of residues 183–294 (containing Rpt I and a portion
of Rpt II) is a MYC-interacting region.10 As Rpt I and II are
imperfect repeats with 40% sequence identity,35 it is possible
MYC can bind either or both regions. Furthermore, INI1 dele-
tion of residues 183–294 retains interaction with MYC in cells,
suggesting other INI1 regions can interact with MYC. This
reflects the multivalent nature of MYC-protein interactions,
seen with other MYC interactors such as TRRAP, BIN1, and
SKP2.9,36-38 The tumor suppressive activity of INI1 is depen-
dent on the Rpt motifs, and truncation and point mutations
affecting these regions are also seen in rhabdoid tumors, rein-
forcing the important role of this region in tumor suppres-
sion.12,39,40 Thus, we show the interaction of MYC and INI1
through two functionally significant regions, the latter of which
Figure 6. MYC and INI1 antagonistically regulate proliferation and transformation. (A) Proliferation of the G401 panel was assessed using a Coulter Counter every 24 hours
to quantitate cell number. Mean cell number § SD for 3 independent experiments performed in triplicate is shown. (B) G401 cells with ectopic MYC and/or INI1 were
grown in 0.3% Noble agar C 10% FBS-DMEM H21 and the number of colonies was scored 3 weeks post-seeding. Mean colony number § SD for 3 independent experi-
ments is shown.  p<0.05,  p<0.01, one-way ANOVA with Bonferroni post test. Representative colony images are shown.
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can be disrupted in tumors with absent or mutated INI1
protein.
MYC is considered a master regulator of transcription as it
binds to and potentially regulates 10–15% of the genome.41,42
Genome-wide analyses of INI1 and other SWI/SNF complex
members also reveal the widespread and diverse nature of their
chromatin binding.25 To further characterize MYC and INI1
transcriptional regulation, we have analyzed genome-wide
datasets and find that a significant portion (26%) of MYC-
bound regions is also bound by INI1. These regions correspond
to both promoter and enhancer regions. The SWI/SNF com-
plex has been implicated in bridging chromosomal looping
interactions.43-46 Thus transcriptional regulation by the MYC-
INI1 complex may also occur through long-range enhancer-
promoter interactions. Target gene analysis indicates the genes
regulated by MYC and INI1 are enriched for those involved in
translation, RNA processing and metabolism, and cell cycle.
These results suggest that INI1 may exert its activity by regulat-
ing a portion of MYC target genes from different genomic reg-
ulatory loci.
INI1 is a potent tumor suppressor. Its biallelic loss is often
the sole genetic feature of rhabdoid tumors, a highly aggressive
pediatric cancer commonly located in the kidney, central ner-
vous system, and other soft tissues.12,15,47,48 This cancer’s poor
outcome and lack of molecular therapeutic targets have
prompted further mechanistic insight into loss-of-INI1-driven
oncogenesis. Our findings relate the opposing transcriptional
regulatory roles of INI1 and MYC to their antagonistic contri-
butions to oncogenic functions. When INI1 is introduced into
INI1-deficient rhabdoid tumor cells, INI1 binds to MYC-bound
target genes and decrease MYC binding to selective target
genes. INI1 also opposingly regulate the expression of MYC
activated genes (including drivers of cell cycle progression, cel-
lular metabolism, and ribosome and RNA processing) and
repressed genes (such as inhibitors of cell cycle progression).
Thus, INI1 may alter MYC binding and/or transcriptional
activity to regulate these genes. Previous studies in rhabdoid
tumors demonstrate that INI1 can mediate cell cycle arrest by
binding and repressing cyclin D1 (CCND1) and activating
cyclin-dependent kinase inhibitors, p16INK4A (CDKN2A) and
p21CIP1 (CDKN1A).49-53 Our results implicate the chromatin
interaction of MYC and INI1 in the regulation of these targets
as well as a broader program of genes involved in cell growth
and proliferation. Functionally, the antagonistic relationship
between MYC and INI1 is reflected in cellular proliferation and
transformation in rhabdoid tumor cells, in which INI1 sup-
presses MYC-potentiated anchorage-independent colony for-
mation. These observations are consistent with genomic
sequencing and expression analyses of primary rhabdoid
tumors, which show an extremely low rate of DNA mutations
accompanying the universal hallmark loss of INI1 activity, yet
up-regulation of MYC target gene network is a feature of these
INI1-deficient tumors.48,54
Collectively, our results demonstrate that MYC and INI1
directly interact, and their regions of interaction map to func-
tionally important regions of both proteins, including the MYC
LZ and the INI1 Rpt motifs. We show that MYC and INI1
antagonistically regulate transcription and oncogenic processes,
which suggests that INI1 mediates tumor suppression in part
through its interaction with MYC to regulate MYC target genes
and biological functions, including proliferation and transfor-
mation. In cancers with loss of INI1 expression, this interaction
would be disrupted and may lead to deregulated MYC activity.
Though the loss of INI1 cannot be therapeutically targeted
directly, our findings suggest that inhibiting MYC may be a
therapeutic target in INI1-deficient tumors such as malignant
rhabdoid tumors that lack treatment options. Recent studies
suggest targeting the MYC pathway at different levels, includ-
ing MYC transcription.55,56 MYC-MAX interaction,57-59 and
downstream functions,60,61 are promising anti-cancer avenues.
Recurrent mutations in other subunits of the SWI/SNF com-
plex have been recently identified in different cancer types.14,15
Understanding the molecular and biological link between MYC
and other SWI/SNF complex subunits may reveal novel
insights into oncogenesis and therapeutic targets.
Materials and methods
Cell culture
Phoenix Eco, HEK293Tv (a kind gift of Dr. Sam Benchimol,
York University), and G401 (a kind gift of Dr. Rod Bremner,
University of Toronto) cells were maintained in Dulbecco’s
Modified Eagle Media (DMEM) H21 supplemented with anti-
biotics (100 U/mL penicillin and 100 mg streptomycin) and
10% fetal bovine serum (FBS; Gibco). HO15.19 cells were cul-
tured in DMEM H21 with antibiotics and 10% calf serum
(Gibco). A549 cells were grown in a-MEM containing 10%
FBS and antibiotics. SK-BR3 cells were maintained in McCoy’s
5A media with 10% FBS and antibiotics. NCI-H520 cells were
cultured in RPMI 1640 with 10% FBS and antibiotics. T47D
cells were maintained in RPMI 1640 with antibiotics, 10% FBS,
and supplemented with 0.2 U/mL human insulin (Sigma
Chemical).
Retroviral infections
Phoenix Eco cells were transfected with retroviral constructs by
calcium phosphate precipitation. Viral supernatant was har-
vested 48 hours post-transfection and used to infect HO15.19
and G401 cells. Cells infected with MYC vectors were selected
by fluorescence activated cell sorting (Becton Dickinson FAC-
StarPlus) for GFP expressed from a bicistronic retroviral vector.
INI1 infected cells were isolated by puromycin selection (1 mg/
mL) (Sigma Chemical).
Plasmids
MYC deletion mutants, D265–317, D371–412, and D414–433,
were subcloned from the vector pDORneo into the retroviral
vector, pBabeMNiresGFP (a kind gift from Dr. Gary
Nolan).62,63 Wild type human MYC cDNA was used as a tem-
plate to produce Db and previously described.64 MYC-EG,
MAX-EG, and MAX plasmids have been previously described.6
pBabepuro-FLAG-INI1 was a kind gift from Dr. Anthony
Imbalzano, University of Massachusetts.65 The coding region
of INI1 was subcloned into the transient expression vector,
CMV10–1XFLAG using EcoRI. The INI1 deletion mutants
CELL CYCLE 1701
were generated by PCR-based site directed mutagenesis as
NLS-Kozak-INI1 fragments and were cloned into the transient
expression vector, CMV10–1XFLAG using EcoRI. The recom-
binant fusion protein, GST-INI1 183–294 was cloned into the
pGEX-2TK expression vector (Amersham Pharmacia); His-
MYC 250–439 and 353–434 were cloned into the pET-15b
expression vector (Novagen) using 50-NdeI and 30-BamHI sites.
Protein extraction and immunoblotting
Whole cell extracts were isolated in Triton buffer (25 mM
HEPES pH 7.7, 0.3 M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA,
0.1% Triton X-100, 0.5 mM DTT, 1X protease inhibitor mix).
Cell fractionations were previously described.66 For co-
immmunoprecipitation, whole cell or nuclear extracts were
harvested in lysis buffer (15 mM Tris-HCl pH 7.4, 0.5 M NaCl,
0.35% IGEPAL, 5 mM EDTA, 5 mM EGTA, 1 mM PMSF, 1X
protease inhibitor mix) and immunoprecipitated using home-
made rabbit polyclonal antibodies raised against MYC (N262),
generated as described elsewhere67 or INI1 and 50 mL of pro-
tein G sepharose (GE Healthcare). After washes, immunopreci-
pitates were analyzed by immunoblotting. For
immunoblotting, protein lysates were quantified by Bradford
protocol, and 40 mg to 50 mg were resolved by SDS-PAGE (7%
to 12%). Antibodies against MYC (9E10, 3C7 made in house;
1:1000), FLAG (Sigma; 1:1000), INI1 (BD Biosciences, Santa
Cruz; 1:500), MAX (Santa Cruz; 1:500), tubulin (Calbiochem;
1:5000), or actin (Sigma; 1:3000). Proteins were visualized by
chemiluminescence reagents (PerkinElmer) and exposed to
BioFlex MSI film (Clonex Corp.), or by IRDye fluorescent sec-
ondary antibodies and Odyssey imager (LI-COR).
Biochemical protein purification
GST fusion proteins were bacterially expressed from pGEX-
INI1 183–294 vector and purified as described elsewhere.68
His-MYC fusion proteins were bacterially expressed from pET-
15b-MYC 250–439 and pET-15b-MYC 353–434 vectors and
purified as described elsewhere.69
Protein-protein interaction analysis
Physical protein-protein interactions were identified using
Interologous Interaction Database (I2D) version 2.2 (http://
ophid.utoronto.ca/i2d).70,71 I2D integrates interaction from
curated databases (e.g. IntAct, BioGRID, MINT, HPRD), high-
throughput datasets (e.g., Y2H, MS), and orthologs across
human, rat, mouse, fly worm, and yeast. In this manuscript, we
only considered experimentally detected interactions, excluding
orthologous predictions. Network analysis and visualization
was performed in NAViGaTOR version 2.3 (http://ophid.utor
onto.ca/navigator).72
ChIP binding region and target gene analyses
ChIP-seq datasets were obtained from the Encyclopedia of
DNA Elements (ENCODE) Consortium26 (MYC ChIP-seq in
HeLa-S3: ENCODE Data Coordination Centre (DCC) acces-
sion: ENCSR000EZD; SMARCB1/INI1 ChIPs-seq in HeLa-S3:
DCC accession: ENCSR000EDK). Overlapping peaks of at least
one nucleotide between 2 datasets were obtained using the
intersection function of BEDTools version 2.18.27 Statistical
analysis for coincident binding was determined using the GSC
test28; statistical significance was determined at p < 0.5. Puta-
tive target genes and genomic regions were identified using
BETA version 1.0.6.29 GO analyses were performed using the
Database for Annotation, Visualization and Integrated Discov-
ery (DAVID) version 6.7.73,74
ChIP-qPCR
ChIP was performed as described previously with slight modifi-
cations.75 Briefly, cells were harvested after crosslinking in 1%
formaldehyde for 15 minutes followed by incubating in
0.125 M glycine for 5 minutes. Ten million (107) cells per ChIP
reaction were lysed, sonicated with Bioruptor Pico (Diage-
node), and incubated with antibodies against MYC (homemade
N262), FLAG (Sigma), or IgG controls (Santa Cruz). After
washes, DNA was purified using QIAquick PCR Purification
Kit (Qiagen) and analyzed by quantitative real-time PCR
(qPCR). Primers used are listed in Table S3.
Gene expression analysis
RNA was isolated using TRIzol and cDNA was synthesized as
per the manufacturer’s protocols (Invitrogen). Gene expression
was analyzed by qPCR and normalized to ACTB. Primers used
are listed in Table S3.
Cellular proliferation
Proliferation of G401 cells infected with MYC or INI1 was
assessed as described elsewhere.76 Population doubling times
were calculated with GraphPad Prism v5.0a.
Colony formation in soft agar
Transformation in G401 cells was performed with seeding of
5,000 cells in 10% FBS DMEM H21 C 0.3% noble agar as
described elsewhere.76
Abbreviations
BETA Binding and Expression Target Analysis
bHLHLZ basic helix-loop-helix leucine zipper
ChIP-seq chromatin immunoprecipitation sequencing
DAVID Database for Annotation, Visualization and Inte-
grated Discovery
ENCODE Encyclopedia of DNA Elements
GFP green fluorescent protein
GO gene ontology
GSC Genome Structure Correction
GST glutathione-S-transferase
I2D Interologous Interaction Database
INI1 integrase interactor-1
MB MYC homology box
MYC c-MYC
NLS nuclear localization signal
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Rpt Repeat motif
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TSS transcriptional start site
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